Published in Proc Natl Acad Sci U S A on December 16, 2004
Severe acute respiratory syndrome coronavirus group-specific open reading frames encode nonessential functions for replication in cell cultures and mice. J Virol (2005) 2.22
Mechanisms of coronavirus cell entry mediated by the viral spike protein. Viruses (2012) 1.55
A conserved trimerization motif controls the topology of short coiled coils. Proc Natl Acad Sci U S A (2005) 1.43
Supramolecular architecture of severe acute respiratory syndrome coronavirus revealed by electron cryomicroscopy. J Virol (2006) 1.34
Binding of a potent small-molecule inhibitor of six-helix bundle formation requires interactions with both heptad-repeats of the RSV fusion protein. Proc Natl Acad Sci U S A (2009) 1.14
Cryo-electron microscopy structure of a coronavirus spike glycoprotein trimer. Nature (2016) 1.12
Amino acid substitutions in the S2 subunit of mouse hepatitis virus variant V51 encode determinants of host range expansion. J Virol (2007) 1.10
Predicting helix orientation for coiled-coil dimers. Proteins (2008) 1.06
Crystal structure of the Marburg virus GP2 core domain in its postfusion conformation. Biochemistry (2012) 0.98
Important role for the transmembrane domain of severe acute respiratory syndrome coronavirus spike protein during entry. J Virol (2006) 0.95
Antigenic modules in the N-terminal S1 region of the transmissible gastroenteritis virus spike protein. J Gen Virol (2011) 0.94
Conformational reorganization of the SARS coronavirus spike following receptor binding: implications for membrane fusion. PLoS One (2007) 0.94
Heptad repeat-derived peptides block protease-mediated direct entry from the cell surface of severe acute respiratory syndrome coronavirus but not entry via the endosomal pathway. J Virol (2007) 0.92
Role of spike protein endodomains in regulating coronavirus entry. J Biol Chem (2009) 0.89
Cooperative involvement of the S1 and S2 subunits of the murine coronavirus spike protein in receptor binding and extended host range. J Virol (2006) 0.88
Functional characterization of heptad repeat 1 and 2 mutants of the spike protein of severe acute respiratory syndrome coronavirus. J Virol (2006) 0.88
Structure, Function, and Evolution of Coronavirus Spike Proteins. Annu Rev Virol (2016) 0.80
Influence of hydrophobic and electrostatic residues on SARS-coronavirus S2 protein stability: insights into mechanisms of general viral fusion and inhibitor design. Protein Sci (2014) 0.78
Dynamics of SARS-coronavirus HR2 domain in the prefusion and transition states. J Magn Reson (2009) 0.77
SARS-CoV fusion peptides induce membrane surface ordering and curvature. Sci Rep (2016) 0.76
SARS-CoV heptad repeat 2 is a trimer of parallel helices. Protein Sci (2011) 0.76
Crucial steps in the structure determination of a coronavirus spike glycoprotein using cryo-electron microscopy. Protein Sci (2016) 0.76
Cryo-electron microscopy structures of the SARS-CoV spike glycoprotein reveal a prerequisite conformational state for receptor binding. Cell Res (2016) 0.75
Sequential activation of the three protomers in the Moloney murine leukemia virus Env. Proc Natl Acad Sci U S A (2017) 0.75
The CCP4 suite: programs for protein crystallography. Acta Crystallogr D Biol Crystallogr (1994) 187.88
Crystallography & NMR system: A new software suite for macromolecular structure determination. Acta Crystallogr D Biol Crystallogr (1998) 169.28
Improved methods for building protein models in electron density maps and the location of errors in these models. Acta Crystallogr A (1991) 119.63
A novel coronavirus associated with severe acute respiratory syndrome. N Engl J Med (2003) 29.55
Automated protein model building combined with iterative structure refinement. Nat Struct Biol (1999) 27.52
Coronavirus as a possible cause of severe acute respiratory syndrome. Lancet (2003) 24.78
Receptor binding and membrane fusion in virus entry: the influenza hemagglutinin. Annu Rev Biochem (2000) 19.03
Characterization of a novel coronavirus associated with severe acute respiratory syndrome. Science (2003) 18.34
Atomic structure of the ectodomain from HIV-1 gp41. Nature (1997) 16.31
Core structure of gp41 from the HIV envelope glycoprotein. Cell (1997) 16.18
Structure of influenza haemagglutinin at the pH of membrane fusion. Nature (1994) 14.61
Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature (2003) 8.77
Aetiology: Koch's postulates fulfilled for SARS virus. Nature (2003) 7.51
The severe acute respiratory syndrome. N Engl J Med (2003) 7.48
Crystal structure of the Ebola virus membrane fusion subunit, GP2, from the envelope glycoprotein ectodomain. Mol Cell (1998) 4.73
The structural biology of type I viral membrane fusion. Nat Rev Mol Cell Biol (2003) 4.21
Structural basis for paramyxovirus-mediated membrane fusion. Mol Cell (1999) 4.17
The coronavirus spike protein is a class I virus fusion protein: structural and functional characterization of the fusion core complex. J Virol (2003) 3.71
A 193-amino acid fragment of the SARS coronavirus S protein efficiently binds angiotensin-converting enzyme 2. J Biol Chem (2003) 3.60
Heptad repeat sequences are located adjacent to hydrophobic regions in several types of virus fusion glycoproteins. J Gen Virol (1990) 3.59
Core structure of the envelope glycoprotein GP2 from Ebola virus at 1.9-A resolution. Proc Natl Acad Sci U S A (1999) 3.23
pH-dependent entry of severe acute respiratory syndrome coronavirus is mediated by the spike glycoprotein and enhanced by dendritic cell transfer through DC-SIGN. J Virol (2004) 3.04
Characterization of severe acute respiratory syndrome-associated coronavirus (SARS-CoV) spike glycoprotein-mediated viral entry. Proc Natl Acad Sci U S A (2004) 3.03
Heptad breaks in alpha-helical coiled coils: stutters and stammers. Proteins (1996) 2.30
Evidence for a coiled-coil structure in the spike proteins of coronaviruses. J Mol Biol (1987) 2.07
A dual-functional paramyxovirus F protein regulatory switch segment: activation and membrane fusion. J Cell Biol (2003) 2.00
Severe acute respiratory syndrome coronavirus (SARS-CoV) infection inhibition using spike protein heptad repeat-derived peptides. Proc Natl Acad Sci U S A (2004) 1.89
Crystal structure of severe acute respiratory syndrome coronavirus spike protein fusion core. J Biol Chem (2004) 1.64
Leash in the groove mechanism of membrane fusion. Nat Struct Biol (2003) 1.36
Covalent trimers of the internal N-terminal trimeric coiled-coil of gp41 and antibodies directed against them are potent inhibitors of HIV envelope-mediated cell fusion. J Biol Chem (2003) 1.34
Enfuvirtide. Nat Rev Drug Discov (2003) 1.22
Structural basis for coronavirus-mediated membrane fusion. Crystal structure of mouse hepatitis virus spike protein fusion core. J Biol Chem (2004) 1.22
Structural characterization of the fusion-active complex of severe acute respiratory syndrome (SARS) coronavirus. Proc Natl Acad Sci U S A (2004) 1.12
De novo design of peptide immunogens that mimic the coiled coil region of human T-cell leukemia virus type-1 glycoprotein 21 transmembrane subunit for induction of native protein reactive neutralizing antibodies. J Biol Chem (2004) 1.01
Structure of unliganded HSV gD reveals a mechanism for receptor-mediated activation of virus entry. EMBO J (2005) 2.95
Structural basis for HIV-1 neutralization by a gp41 fusion intermediate-directed antibody. Nat Struct Mol Biol (2006) 2.50
Structural and functional analysis of the human HDAC4 catalytic domain reveals a regulatory structural zinc-binding domain. J Biol Chem (2008) 2.09
Structural analysis of the epitope of the anti-HIV antibody 2F5 sheds light into its mechanism of neutralization and HIV fusion. J Mol Biol (2003) 2.03
Substrate binding to histone deacetylases as shown by the crystal structure of the HDAC8-substrate complex. EMBO Rep (2007) 2.01
A human monoclonal antibody neutralizes diverse HIV-1 isolates by binding a critical gp41 epitope. Proc Natl Acad Sci U S A (2005) 1.74
Glucagon-like peptide 1/glucagon receptor dual agonism reverses obesity in mice. Diabetes (2009) 1.65
Addition of a cholesterol group to an HIV-1 peptide fusion inhibitor dramatically increases its antiviral potency. Proc Natl Acad Sci U S A (2009) 1.55
Interdomain communication in hepatitis C virus polymerase abolished by small molecule inhibitors bound to a novel allosteric site. J Biol Chem (2005) 1.54
Molecular insights into substrate recognition and catalysis by tryptophan 2,3-dioxygenase. Proc Natl Acad Sci U S A (2006) 1.50
Combinatorial control of Th17 and Th1 cell functions by genetic variations in genes associated with the interleukin-23 signaling pathway in spondyloarthritis. Arthritis Rheum (2013) 1.44
Structural and biochemical characterization of the wild type PCSK9-EGF(AB) complex and natural familial hypercholesterolemia mutants. J Biol Chem (2008) 1.41
Chromatin remodeling by the SWI/SNF-like BAF complex and STAT4 activation synergistically induce IL-12Rbeta2 expression during human Th1 cell differentiation. EMBO J (2007) 1.36
Vaccination with peptide mimetics of the gp41 prehairpin fusion intermediate yields neutralizing antisera against HIV-1 isolates. Proc Natl Acad Sci U S A (2010) 1.36
Covalent stabilization of coiled coils of the HIV gp41 N region yields extremely potent and broad inhibitors of viral infection. Proc Natl Acad Sci U S A (2005) 1.36
RanBPM is a phosphoprotein that associates with the plasma membrane and interacts with the integrin LFA-1. J Biol Chem (2004) 1.35
A proprotein convertase subtilisin-like/kexin type 9 (PCSK9) C-terminal domain antibody antigen-binding fragment inhibits PCSK9 internalization and restores low density lipoprotein uptake. J Biol Chem (2010) 1.32
Mechanistic implications for LDL receptor degradation from the PCSK9/LDLR structure at neutral pH. EMBO Rep (2011) 1.31
Analysis of the HIV-1 gp41 specific immune response using a multiplexed antibody detection assay. J Immunol Methods (2004) 1.29
A PCSK9-binding antibody that structurally mimics the EGF(A) domain of LDL-receptor reduces LDL cholesterol in vivo. J Lipid Res (2010) 1.29
The COP9 signalosome regulates Skp2 levels and proliferation of human cells. J Biol Chem (2006) 1.25
Inhibition of Nipah virus infection in vivo: targeting an early stage of paramyxovirus fusion activation during viral entry. PLoS Pathog (2010) 1.25
Advances in the development of new therapeutic agents targeting the NS3-4A serine protease or the NS5B RNA-dependent RNA polymerase of the hepatitis C virus. Adv Drug Deliv Rev (2007) 1.24
Multiparameter single-cell profiling of human CD4+FOXP3+ regulatory T-cell populations in homeostatic conditions and during graft-versus-host disease. Blood (2013) 1.16
Progress towards the development of a HIV-1 gp41-directed vaccine. Curr HIV Res (2004) 1.13
Structural characterization of the fusion-active complex of severe acute respiratory syndrome (SARS) coronavirus. Proc Natl Acad Sci U S A (2004) 1.12
A fragment of the scaffolding protein RanBP9 is increased in Alzheimer's disease brains and strongly potentiates amyloid-beta peptide generation. FASEB J (2009) 1.12
Viral entry inhibitors targeted to the membrane site of action. J Virol (2010) 1.10
2-Trifluoroacetylthiophenes, a novel series of potent and selective class II histone deacetylase inhibitors. Bioorg Med Chem Lett (2008) 1.08
Universal influenza B vaccine based on the maturational cleavage site of the hemagglutinin precursor. J Virol (2005) 1.07
Capturing a fusion intermediate of influenza hemagglutinin with a cholesterol-conjugated peptide, a new antiviral strategy for influenza virus. J Biol Chem (2011) 1.06
Spring-loaded model revisited: paramyxovirus fusion requires engagement of a receptor binding protein beyond initial triggering of the fusion protein. J Virol (2011) 1.06
RanBPM associates with CD39 and modulates ecto-nucleotidase activity. Biochem J (2006) 1.05
Bone morphogenic protein antagonist Drm/gremlin is a novel proangiogenic factor. Blood (2006) 1.04
Protein minimization of the gp120 binding region of human CD4. Biochemistry (2005) 0.99
Genetic and epigenetic networks controlling T helper 1 cell differentiation. Immunology (2009) 0.98
Role of RanBP9 on amyloidogenic processing of APP and synaptic protein levels in the mouse brain. FASEB J (2012) 0.98
Enhancement of transactivation activity of Rta of Epstein-Barr virus by RanBPM. J Mol Biol (2008) 0.98
COP9 signalosome subunit 5 (CSN5/Jab1) regulates the development of the Drosophila immune system: effects on Cactus, Dorsal and hematopoiesis. Genes Cells (2007) 0.97
Affinity maturation and characterization of a human monoclonal antibody against HIV-1 gp41. MAbs (2009) 0.95
Experience of an information aid for newly diagnosed multiple sclerosis patients: a qualitative study on the SIMS-Trial. Health Expect (2011) 0.93
Histidine 55 of tryptophan 2,3-dioxygenase is not an active site base but regulates catalysis by controlling substrate binding. Biochemistry (2008) 0.93
Entry of herpesviruses into cells: the enigma variations. Adv Exp Med Biol (2013) 0.92
Integration of distinct intracellular signaling pathways at distal regulatory elements directs T-bet expression in human CD4+ T cells. J Immunol (2009) 0.92
The glucagon receptor is involved in mediating the body weight-lowering effects of oxyntomodulin. Obesity (Silver Spring) (2012) 0.90
Short communication: In vitro synergy between peptides or neutralizing antibodies targeting the N- and C-terminal heptad repeats of HIV Type 1 gp41. AIDS Res Hum Retroviruses (2008) 0.89
An intracellular role for the C1q-globular domain. Cell Signal (2006) 0.87
Regulation of mu opioid receptor internalization by the scaffold protein RanBPM. Neurosci Lett (2009) 0.87
Fatal measles virus infection prevented by brain-penetrant fusion inhibitors. J Virol (2013) 0.87
Expression pattern of the JAB1/CSN5 gene during murine embryogenesis: colocalization with NEDD8. Gene Expr Patterns (2004) 0.86
COPS5 (Jab1) protein increases β site processing of amyloid precursor protein and amyloid β peptide generation by stabilizing RanBP9 protein levels. J Biol Chem (2013) 0.86
Structural basis for resistance of the genotype 2b hepatitis C virus NS5B polymerase to site A non-nucleoside inhibitors. J Mol Biol (2009) 0.86
RanBPM regulates the progression of neuronal precursors through M-phase at the surface of the neocortical ventricular zone. Dev Neurobiol (2010) 0.85
DPP-IV-resistant, long-acting oxyntomodulin derivatives. J Pept Sci (2011) 0.84
Inhibiting viral proteases: challenges and opportunities. Biopolymers (2002) 0.83
PEGylation of Neuromedin U yields a promising candidate for the treatment of obesity and diabetes. Bioorg Med Chem (2012) 0.83
Induction of conformational changes at the N-terminus of herpes simplex virus glycoprotein D upon binding to HVEM and nectin-1. Virology (2013) 0.81
ApoA-I mimetic peptides promote pre-β HDL formation in vivo causing remodeling of HDL and triglyceride accumulation at higher dose. Bioorg Med Chem (2010) 0.81
Rapid screening for entry inhibitors of highly pathogenic viruses under low-level biocontainment. PLoS One (2012) 0.81
2-D Difference in gel electrophoresis combined with Pro-Q Diamond staining: a successful approach for the identification of kinase/phosphatase targets. Electrophoresis (2009) 0.81
Development of a neuromedin U-human serum albumin conjugate as a long-acting candidate for the treatment of obesity and diabetes. Comparison with the PEGylated peptide. J Pept Sci (2013) 0.81
A PEGylated analog of the gut hormone oxyntomodulin with long-lasting antihyperglycemic, insulinotropic and anorexigenic activity. Bioorg Med Chem (2013) 0.80
Talking about end-of-life preferences with advanced cancer patients: factors influencing feasibility. J Pain Symptom Manage (2012) 0.80
Improvement of HIV fusion inhibitor C34 efficacy by membrane anchoring and enhanced exposure. J Antimicrob Chemother (2014) 0.79
Immunization against proprotein convertase subtilisin-like/kexin type 9 lowers plasma LDL-cholesterol levels in mice. J Lipid Res (2012) 0.79
RanBP9 Plays a Critical Role in Neonatal Brain Development in Mice. PLoS One (2013) 0.79
Infection of primary neurons mediated by nipah virus envelope proteins: role of host target cells in antiviral action. J Virol (2011) 0.79
Synthetic peptide vaccines: the quest to develop peptide vaccines for influenza, HIV and Alzheimer's disease. Adv Exp Med Biol (2009) 0.79
Prime site binding inhibitors of a serine protease: NS3/4A of hepatitis C virus. Biochemistry (2002) 0.79
Oxygen activation in neuronal NO synthase: resolving the consecutive mono-oxygenation steps. Biochem J (2012) 0.78
The effect of prime-site occupancy on the hepatitis C virus NS3 protease structure. Protein Sci (2002) 0.77